Novavax, Inc. has been awarded a contract by the U.S. Department of Defense (DoD) for the manufacture of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its nanoparticle technology and includes Novavax’ Matrix‑M adjuvant. JPEO-CRBND-EB through funding provided by the Defense Health Program, has agreed to fund as much as $60 million to support Novavax in its production of several components of the vaccine that will be manu...